Quibim announces QP-Prostate® availability through Precision Imaging Network, part of Microsoft’s diagnostic imaging and radiology solutions
Healthcare organizations in North America can select QP-Prostate® for use within supported imaging workflows.
Valencia, Spain, November 10, 2026 – Quibim today announced that QP-Prostate®, is available in North America through Precision Imaging Network, part of Microsoft’s clinical applications focused on diagnostic imaging and radiology.
Nathan Clark, CCO of Quibim, said, “Making imaging AI easier to adopt is just as important as the technology itself. Healthcare organizations in North America can now select QP-Prostate® through Precision Imaging Network and enable it within their supported imaging workflows. It supports radiologists and urologists in detecting, locating, and characterizing lesions suspicious for cancer on prostate MRI, while diagnostic and patient management decisions remain with the physician.”
When organizations select and purchase QP-Prostate® from Microsoft, they can enable and configure the application’s supported workflow through Precision Imaging Network.
Precision Imaging Network provides organizations access to a collection of third-party imaging AI applications that perform different kinds of clinical image analysis. Using existing image sharing infrastructure, Precision Imaging Network routes imaging studies to the applications an organization has selected, then manages and routes the results those applications generate to supported clinical workflows.
In a supported, enabled configuration, results from QP-Prostate® can be delivered to PowerScribe, Microsoft’s leading radiology reporting solution used by hundreds of healthcare organizations. Radiologists can review and incorporate the desired results directly in their PowerScribe report before finalizing it. Availability of this functionality depends on the application, supported software configuration, and the healthcare organization’s deployment.
“Healthcare organizations need a practical way to adopt a variety of imaging AI applications,” says Vikram Chhabra, Vice President, Medical Imaging AI Solutions at Microsoft. “Precision Imaging Network brings a platform approach to AI adoption, connecting organizations to third-party applications through a streamlined integration within existing clinical workflows.”
About QP-Prostate®
Quibim develops QP-Prostate®, an AI-based computer-aided detection and diagnosis (CADe/CADx) image processing software for concurrent reading by physicians with proper training as an aid for interpreting prostate MRI studies. The software automatically detects and identifies suspected lesions in the prostate gland based on bi-parametric prostate MRI, marking them as an overlay onto the source MR images; patient management decisions should not be based solely on its results. In the United States, the QP-Prostate® application is 510(k)-cleared (K242683 and K203582) as a Class II; and in Canada, QP-Prostate® holds a Class 3 Medical Device License (No. 115556).
For information about QP-Prostate®, availability in the US and Canada, and supported configurations, visit quibim.ai.
About Quibim
Quibim is a company designing pioneering tools that unlock imaging data to improve patient outcomes. With offices in New York, Cambridge (UK), Valencia, Madrid, and Barcelona (Spain), the company was born from the ambition of turning imaging into a catalyst for precision health. Quibim leads the forefront of imaging biomarkers research in life sciences, pioneering the development of advanced algorithms that transform imaging data into actionable predictions in oncology, immunology and neurology. The company leverages the capabilities of MRI, CT, and PET imaging to create regulatory-cleared Medical Devices that are seamlessly integrated into the workflows of healthcare providers worldwide. More than 470 sites are using Quibim products globally.